RET and medullary thyroid gland carcinoma: The vast majority of MTC cases resistant to selpercatinib or pralsetinib are RET-mutant negative; further investigation of RET-independent resistance mechanisms has demonstrated that the resistance to selective RET inhibition may be driven by acquired MET or KRAS amplifications (Lin et al. 2020).